Chordia Therapeutics Inc.
Code | Sector | Market |
---|---|---|
190A | Pharmaceuticals | Growth |
Date of listing approval | 2024/05/10 |
---|---|
Expected Date | 2024/06/14 |
Lead Underwriter | SBI SECURITIES Co.,Ltd. |
Description |
Listed Shares(total) | 10,465,000 |
---|---|
Trading Unit | 100 |
New Shares | 9,100,000 |
Existing Shares | 1,365,000¡Êonly O.A.¡Ë |
Shares Outstanding | PreIPO 56,443,800.00 |
PostIPO 65,543,800.00 | |
Paid Up Capital | PreIPO Y90,000,000 |
PostIPO Y659,205,288 | |
Expected Pricing Date | 2024/05/28 |
Book Building Start | 2024/05/30 |
Book Building End | 2024/06/05 |
Fix Date | 2024/06/06 |
Offering Starts | 2024/00/7 |
Offering Ends | 2024/06/12 |
Expect Pricing | Y143-Y153 |
Notional PER (based on previous period) |
36.11-38.64 |
Notional PER(based on results forecast) | -3.54--3.79 |
Offering Price | Y153 |
Offering Price PER (based on previous period) |
-3.54--3.79 |
Offering Price PBR (based on previous period) |
1.93 |
Offering Price PER (based on results forecast) |
-3.79 |
Use of Funds Raised |
Financial Data
Units:Y1,000
Fiscal Year End:2021/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 800,000 |
Current Profit | - | -525,207 |
Net Profit | - | -527,107 |
Net Assets | - | 2,056,435 |
Fiscal Year End:2022/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | |
Current Profit | - | -1,776,640 |
Net Profit | - | -1,779,060 |
Net Assets | - | 4,277,539 |
Fiscal Year End:2023/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 2,500,000 |
Current Profit | - | 225,761 |
Net Profit | - | 223,341 |
Net Assets | - | 4,500,881 |
Recent Quarter 2024/02 |
||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | |
Current Profit | - | -801,401 |
Net Profit | - | -802,611 |
Net Assets | - | 3,698,270 |
Results Forecast 2024/08 |
||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | |
Current Profit | - | -2,278,000 |
Net Profit | - | -2,280,000 |
Net Assets | - | - |
Per Share Units:Y1
Fiscal Year End:2021/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -15.08 | -58.19 |
Fiscal Year End:2022/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -39.78 | -72.35 |
Fiscal Year End:2023/08 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | 3.96 | 79.28 |
Fiscal Year End:Interim Results 2024/02 |
||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | ||
Net Earning | - | -14.22 |
Equity | - | - |
Fiscal Year End:Results Forecast 2024/08 |
||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | -40.40 |
Equity | - | - |
Comment
¢£Over allotment(1,365,000) |
Consolidated Subsidiaries
Name | Address |
---|
Underwriters
Allocation | Underwriter | Tel |
---|---|---|
0% | Nomura | 03-3211-1811 |
85% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
5% | Nomura | 03-3211-1811 |
5% | Mizuho | 03-5208-3210 |
0.5% | Akatsuki Securities | 03-5641-7800 |
0.5% | IwaiCosmo Securities Co.,Ltd. | 06-6229-2890 |
0.5% | Okasan | 03-3272-2211 |
0.5% | Kyokuto | 03-3667-9171 |
0.5% | Toyo | 03-5117-1040 |
0.5% | Hirota | 06-6201-1181 |
0.5% | Matsui | 03-5216-0606 |
0.5% | Marusan | 03-3272-5211 |
0.5% | Mito | 03-6739-0310 |
0.5% | Rakuten Securities | 03-6406-2681 |
Data
Date of incorporation | 2017/10/12 |
---|---|
Company address | Kanagawa 251-0012 |
Telephone | 03-6661-9543 |
President | |
Homepage | https://www.chordiatherapeutics.com/ |
Auditor | Azsa |
Major Shareholders | |
---|---|
Shareholder Name | Ratio |
86.62% | |
14.71% | |
12.38% | |
10.27% | |
7.86% | |
7.18% | |
6.55% | |
6.19% | |
6.12% | |
5.24% | |
4.14% |
Number of Employees | 21 as of 2024/03/31 |
---|---|
Birth Date of Representative | 1970/06/25 |